Vaccines against HPV and HPV-related diseases

Patent metadata

Field	Value
Publication number	US-12214034-B2
Application number	US-202318329696-A
Country	US
Kind code	B2
Filing date	Jun 6, 2023
Priority date	Jan 13, 2014
Publication date	Feb 4, 2025
Grant date	Feb 4, 2025

Abstract

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

First claim

What is claimed is:

1. One or more nucleic acids encoding a fusion protein comprising an anti-CD40antibody or fragment thereof, comprising at least three complementarity determining regions (CDRs) from each of a heavy and light chain of an anti-CD40 antibody, at least one peptide linker and at least one human papillomavirus (HPV) E6 antigen and at least one HPV E7 antigen, wherein the E6 and E7 antigens comprise an antigen with at least 90% sequence identity to SEQ ID NO: 1 and an antigen with at least 90% sequence identity to SEQ ID NO:2; and
wherein the fusion protein comprises an amino acid sequence that has at least 95% sequence identity to SEQ ID NO: 19.

2. The one or more nucleic acids of claim 1 , wherein the anti-CD40 antibody or fragment thereof is humanized.

3. The one or more nucleic acids of claim 1 , wherein the fusion protein comprises peptide linkers comprising the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:6.

4. The one or more nucleic acids of claim 1 , wherein the three CDRs from the heavy chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 14-16, and wherein the three CDRs from the light chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 11-13.

5. One or more nucleic acids encoding a fusion protein comprising an anti-CD40antibody or fragment thereof, comprising at least three complementarity determining regions (CDRs) from each of a heavy and light chain of an anti-CD40 antibody, at least one peptide linker and at least one human papillomavirus (HPV) E6 antigen and at least one HPV E7 antigen, wherein the E6 and E7 antigens comprise an antigen with at least 90% sequence identity to SEQ ID NO: 3 and an antigen with at least 90% sequence identity to SEQ ID NO:4; and wherein the fusion protein comprises an amino acid sequence that has at least 95% sequence identity to SEQ ID NO:21.

6. The one or more nucleic acids of claim 5 , wherein the anti-CD40 antibody or fragment thereof is humanized.

7. The one or more nucleic acids of claim 5 , wherein the three CDRs from the heavy chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 14-16, and wherein the three CDRs from the light chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 11-13.

8. The one or more nucleic acids of claim 5 , wherein the fusion protein comprises peptide linkers comprising the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:6.

9. The one or more nucleic acids of claim 5 , wherein the three CDRs from the heavy chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 14-16, and wherein the three CDRs from the light chain of the anti-CD40 antibody comprises the amino acid sequences of SEQ ID NOs: 11-13.

10. A vector comprising the one or more nucleic acids of claim 1 .

11. A vector comprising the one or more nucleic acids of claim 5 .

12. An isolated host cell comprising the one or more nucleic acids of claim 1 .

13. An isolated host cell comprising the one or more nucleic acids of claim 5 .

14. A method of making a fusion protein comprising expressing the one or more nucleic acids of claim 1 in a host cell and isolating the fusion protein.

15. A method of making a fusion protein comprising expressing the one or more nucleic acids of claim 5 in a host cell and isolating the fusion protein.

16. A method of making a fusion protein comprising incubating an host cell comprising the one or more nucleic acids of claim 1 and isolating the fusion protein.

17. A method of making a fusion protein comprising incubating an host cell comprising the one or more nucleic acids of claim 5 and isolating the fusion protein.

Assignees

• Baylor Res Institute

Inventors

• Oh Sangkon
• Zurawski Sandra
• Zurawski Gerard

Classifications

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K2319/91

  containing a motif for glycosylation · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title